id: alcohol_use_disorder_to_NEW:alcohol_related_liver_disease_progression
name: Alcohol Use Disorder (Hazardous Drinking) â†’ Alcohol-Related Liver Disease Progression
from_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder (Hazardous Drinking)
to_node:
  node_id: NEW:alcohol_related_liver_disease_progression
  node_name: Alcohol-Related Liver Disease Progression
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Chronic hazardous alcohol consumption initiates hepatic injury through
  direct hepatotoxic effects of ethanol and its metabolites (acetaldehyde)'
- 'Step 2: Initial liver damage manifests as hepatic steatosis (fatty liver), present
  in approximately 27% of hazardous drinkers'
- 'Step 3: Continued alcohol exposure triggers inflammatory responses, progressing
  to steatohepatitis (24% prevalence) with annualized progression rates of 10% to
  cirrhosis'
- 'Step 4: Persistent inflammation leads to hepatic fibrosis (8% annual progression
  to cirrhosis) through activation of hepatic stellate cells and collagen deposition'
- 'Step 5: Progressive fibrosis culminates in cirrhosis (26% prevalence among hazardous
  drinkers), with associated mortality of 8% annually'
evidence:
  quality_rating: A
  n_studies: 37
  primary_citation: 'Parker R et al. 2019. Natural history of histologically proven
    alcohol-related liver disease: A systematic review. Journal of hepatology.'
  supporting_citations: []
description: 'Systematic review of 37 studies (n=7,528) demonstrates that hazardous
  drinking leads to progressive alcohol-related liver disease through a stepwise histological
  progression. Among hazardous drinkers, 15% have normal histology, 27% steatosis,
  24% steatohepatitis, and 26% cirrhosis. Annual progression rates to cirrhosis increase
  with disease severity: 1% for normal histology, 3% for steatosis, 10% for steatohepatitis,
  and 8% for fibrosis. Steatohepatitis requiring hospitalization represents the most
  dangerous subtype with 15% annual mortality. Even ''benign'' steatosis carries significant
  mortality risk (6% annually), with non-liver mortality (5%) exceeding liver-specific
  mortality (1%).'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 10.0
    type: annualized_progression_rate_percent
    ci_lower: 6.0
    ci_upper: 17.0
  p_value: null
  sample_size: 7528
moderators:
- name: Disease stage at presentation
  direction: strengthens
  strength: strong
  description: Steatohepatitis has highest progression rate (10% annual) compared
    to steatosis (3%) or normal histology (1%)
- name: Clinical setting (inpatient vs outpatient)
  direction: strengthens
  strength: strong
  description: Inpatient cohorts with steatohepatitis show markedly higher annual
    mortality (15%) compared to mixed cohorts (5%)
- name: Presence of fibrosis
  direction: strengthens
  strength: moderate
  description: Fibrosis carries 8% annual progression to cirrhosis compared to 3%
    for simple steatosis
